These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18984771)

  • 1. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
    Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
    J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation.
    Vendrell JA; Magnino F; Danis E; Duchesne MJ; Pinloche S; Pons M; Birnbaum D; Nguyen C; Theillet C; Cohen PA
    J Mol Endocrinol; 2004 Apr; 32(2):397-414. PubMed ID: 15072547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
    Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA
    Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
    Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
    Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient downregulation of ErbB-2 induces TACC1 upregulation in breast cancer cell lines.
    Xiang J; Qiu W; Wang X; Zhou F; Wang Z; Liu S; Yue L
    Oncol Rep; 2013 Apr; 29(4):1517-23. PubMed ID: 23354013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
    Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM
    Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
    McClelland RA; Manning DL; Gee JM; Anderson E; Clarke R; Howell A; Dowsett M; Robertson JF; Blamey RW; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 1996; 41(1):31-41. PubMed ID: 8932874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
    Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
    J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
    Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
    BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
    Jansen MP; Ruigrok-Ritstier K; Dorssers LC; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Helleman J; Sleijfer S; Klijn JG; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2009 Jul; 116(2):263-71. PubMed ID: 18629630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.
    Nagelkerke A; Sieuwerts AM; Bussink J; Sweep FC; Look MP; Foekens JA; Martens JW; Span PN
    Endocr Relat Cancer; 2014 Feb; 21(1):101-12. PubMed ID: 24434718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
    Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
    Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.